Theriva Biologics, Inc. · AMEX:TOVX
Theriva Biologics — Investor Presentation (May 2025)
56 slides from Theriva Biologics's investor presentation, May 2025
Slide 1: Corporate Overview
Corporate Overview © Theriva BIOLOGICS
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward- looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “antici
Slide 3: Theriva Biologics develops oncolytic virus therapeutics targeting solid tumors
Theriva™ Biologics develops unique oncolytic virus therapeutics targeting solid tumors VCN-01 (zabilugene almadenorepvec) BIOLOGICS
Slide 4: Overview
OVERVIEW “ VCN-01 Completed Phase 2b clinical trial . . . oe a. . : : Financial Snapshot in first-line metastatic pancreatic cancer in combination with SoC chemotherapy . Exchange NYSE American Ticker TOVX . VCN-O1 Phase 1 clinical trials support . multiple additional indications (CRC, Cash (12/31/2
Slide 5: Pipeline
Candidate Target Pre-IND Phase 1 Phase 2 Phase 3 Sites Status* Phase 2b enrollment complete Pancreatic Cancer (IV) with Multicenter Orphan Drug Designation US, EU gemcitabine/nab-paclitaxel Spain, USA Fast Track Designation US Phase 1 Complete, CSR in preparation Retinoblastoma (IVit) Orphan Drug De
Slide 6: VCN-01 is a uniquely engineered human adenovirus
VCN-01 IS A UNIQUELY ENGINEERED HUMAN ADENOVIRUS 5 High dose, highly replicating virus designed to destroys cancer cells Systemic VCN-01 targets both primary and metastatic lesions A Virus replicates only in tumor cells Sel ective Liver detargeted : Replicating virus expresses PH20 hyaluronidase Str
Slide 7: VCN-01 is a uniquely engineered human adenovirus
VCN-01 IS A UNIQUELY ENGINEERED HUMAN ADENOVIRUS 5 SYSTEMIC delivers VCN-01 to the primary tumor and 2 } SELECTIVE replication at very high levels lyses tumor metastases and detargets the liver cells directly without harming healthy tissues Tumor Surrounded by STROMA —_ > ., Cancer Associated © Ther
Slide 8: VCN-01 designed to have multiple anti-tumor actions
VCN-01 DESIGNED TO HAVE MULTIPLE ANTI-TUMOR ACTIONS STROMA degradation by PH20 facilitates solid tumor IMMUNOGENIC actions of VCN-01 turn “cold” tumors access and destruction by coadministered cancer therapies “hot” and elicit an anti-tumor immune response Q 2 *3_£)9" nab-paclitaxel > gemcitabine Tu
Slide 9: VCN-01 extensive clinical program
VCN-01 EXTENSIVE CLINICAL PROGRAM 142 patients treated with VCN-01 to date in multiple indications and combinations Savt3oan de Dw & Lead Indication for Phase 3 Rb - IVit BRAIN TUMORS - IV (1)* alone (9)/ COLORECTAL - IV Mn Alone (15) UNIVERSITY OF LEEDS HEAD & NECK - IV alone (1) HEAD & NECK - IV P
Slide 10: VCN-01 in Metastatic Pancreatic Cancer
VCN-01 IN METASTATIC PANCREATIC CANCER @ Theriva
Slide 11: VCN-01 lead indication pancreatic cancer
VCN-01 LEAD INDICATION PANCREATIC CANCER Highly fatal cancer protected by dense tumor stroma * Orphan disease, highest mortality of all solid tumors * Median survival 8-11 months for metastatic disease'? ° USA est. 66,440 new cases and 51,750 deaths in 20243 ° Hyaluronic acid in stroma is associated
Slide 12: Treatment schedule diagram
¹ ² ³ | | | | | | Cycle 1 Day 1 8 15 22 29 36
Slide 13: VIRAGE pancreatic cancer Phase 2b clinical trial
VIRAGE PANCREATIC CANCER PHASE 2B CLINICAL TRIAL Multicenter, open-label, randomized, controlled trial (NCT05673811) ° Patients with newly-diagnosed metastatic pancreatic ductal adenocarcinoma (first line) * Direct comparison of up to two doses of VCN-01 with gemcitabine/nab-paclitaxel standard of c
Slide 14: Patient enrollment by country
Parameter Spain USA Total Sites Open 10 7 17 Screened 131 40 171 Screen Failure 42 (32%) 17 (43%) 59 (35%) Randomized 89 23 112 SoC 44 11 55 VCN-01 + SoC 45 12 57 Treated* SoC 41 7 48 VCN-01 + SoC 39 9 48
Slide 15: Patient demographics statistics
SoC VCN-01 + SoC Combined Statistics (n=48) (n=48) (n=96) Age (years) n 48 48 96 Mean (SD) 69.5 (8.25) 66.0 (8.97) 67.8 (8.75) Median 68.5 66.0 67.5 Gender Male n (%) 22 (45.8) 23 (47.9) 45 (46.9) Female n (%) 26 (54.2) 25 (52.1) 51 (53.1) ECOG at randomization 0 n (%) 17 (35.4) 19 (39.6) 36 (37.5)
Slide 16: Adverse events by preferred term
Preferred Term – No. Patients (%)a,b All Grades Grade 3-4 First Dose Second Dose First Dose Second Dose (n=53) (n=36) (n=53) (n=36) Pyrexia 31 (58.5%) 19 (52.7%) 1 (1.9%) - Nausea 16 (30.2%) 6 (16.6%) - - Asthenia 15 (28.3%) 4 (11.1%) 1 (1.9%) 1 (2.8%) Vomiting 14 (26.4%) 9 (25.0%) - - Aspartate ami
Slide 17: VIRAGE safety review by independent DMC
VIRAGE SAFETY REVIEW BY INDEPENDENT DMC ¢ VIRAGE clinical data was reviewed on two occasions by an independent Data Monitoring Committee (DMC) who noted the following: ° Intravenous VCN-01 was well tolerated in patients treated in this study ° The most common VCN-01 related AEs (pyrexia, flu-like il
Slide 18: Progression free survival
Treatment Events / Median Adj HR Arm Total (95% CI) (95% CI) SoC 41 / 48 4.6 (3.5-6.5) Ref. VCN-01 + SoC VCN-01 33 / 48 7.0 (4.8-11.2) 0.55 (0.34-0.88) + SoC Logrank P-value: 0.0105 SoC + Censor
Slide 19: Overall survival
Treatment Events / Median Adj HR Arm Total (95% CI) (95% CI) VCN-01 + SoC SoC 35 / 48 8.6 (6.9-11.6) Ref. VCN-01 27 / 48 10.8 (7.4-15.8) 0.57 (0.34-0.96) + SoC SoC Logrank P-value: 0.0546 + Censor
Slide 20: Duration of response
Treatment Events / Median Adj HR VCN-01 + SoC Arm Total (95% CI) (95% CI) SoC 11 / 15 5.4 (2.0-6.8) Ref. VCN-01 7 / 19 11.2 (7.4-NE) 0.22 (0.08-0.62) + SoC SoC Logrank P-value: 0.0035 + Censor
Slide 21: VIRAGE analysis of patients receiving two VCN-01 doses
VIRAGE ANALYSIS OF PTS RECEVING TWO VCN-01 DOSES Evaluate the impact of the second VCN-01 dose VCN-01 2 Doses Analysis TREATMENT Cycle 1 2 = = pascwos I Day T 8 15 T 1 & ven-01 1x10 vpby IV infusion. CES nab-Paclitaxel lV followed by gemcitabine WV per SoC.) Continue SoC until disease progression or
Slide 22: Two-dose cohort demographics
Statistics SoC VCN-01 + SoC Combined No. Patients (% of cohort) n (%) 29 (60.4) 34 (70.8) 63 (65.6) Age (years) Mean (SD) 68.1 (8.31) 65.8 (9.71) 66.9 (9.09) Median 66.0 66.0 66.0 Gender Male n (%) 13 (44.8) 17 (50.0) 30 (47.6) Female n (%) 16 (55.2) 17 (50.0) 33 (52.4) ECOG at randomization 0 n (%)
Slide 23: Two-dose PFS analysis
Treatment Events / Median Adj HR Arm Total (95% CI) (95% CI) VCN-01 2 doses + SoC SoC 22 / 29 7.4 (5.7-8.4) Ref. VCN-01 x 2 19 / 34 11.2 (7.3-16.6) 0.48 (0.25-0.91) + SoC Logrank P-value: 0.0173 SoC + Censor
Slide 24: Two-dose OS analysis
VCN-01 2 doses + SoC Treatment Events / Median Adj HR Arm Total (95% CI) (95% CI) SoC 19 / 29 11.6 (8.6-12.8) Ref. VCN-01 x 2 15 / 34 14.8 (10.6-NE) 0.44 (0.21-0.92) + SoC Logrank P-value: 0.0460 SoC + Censor
Slide 25: VIRAGE results support VCN-01 Phase 3 trial in PDAC
VIRAGE RESULTS SUPPORT VCN-01 PHASE 3 TRIAL IN PDAC ¢ Enrolled a “real world” population of older and more fragile patients ° Acceptable AE profile consistent with prior VCN-01 clinical trials ° Increased OS, PFS, and DoR in VCN-01 plus gemcitabine/nab-paclitaxel SoC treatment group compared to SoC
Slide 26: VCN-X Next Generation OV Discovery Platform
@ Theriva VCN-X NEXT GENERATION OV DISCOVERY PLATFORM
Slide 27: Theriva OV pipeline discovery and development
THERIVA OV PIPELINE DISCOVERY AND DEVELOPMENT Advancing founders’ decades of world leading OV innovation Clinically-tested Adenovirus Expressing PH20 +f . Hyaluronidase to Degrade Tumor Stroma VCN-01 Hyaluronidase alone + Additional Transgene Payloads to Enhance Anti-tumor Immune Response and Potent
Slide 28: Albumin binding domain coating protects OV
• OV Parent oncolytic virus (OV) susceptible to neutralizing antibodies • • Albumin binding domain (ABD) OV-ABD expressed on the virus surface (hexon) • • ABD binds serum albumin ⚫ to form a Y OV-ABD coating that protects against neutralizing antibodies Y
Slide 29: Theriva Summary
THERIVA SUMMARY © Theriva BIOLOGICS
Slide 30: Theriva OV portfolio highlights
THERIVA OV PORTFOLIO HIGHLIGHTS Multiple modes of action, indications and combinations Highly differentiated OVs designed to have multiple antitumor effects oe Systemic administration, selective tumor replication, stroma degradation Multiple potential value opportunities for lead asset VCN-01 Phase,
Slide 31: Achievements and projected milestones
ACHIEVEMENTS AND PROJECTED MILESTONES VCN-01 PDAC Phase 3 first patients dosed* VCN-01 EMA Sci Advice Phase 3 study design VCN-01 EOP2 and SA Phase 3 study design 5.4 VIRAGE Topline Data efficacy and safety VIRAGE 2-4 DMC safety evaluation VCN-01 CMC Scale-up feasibility at 200L scale SYN-004 in all
Slide 32: Appendix
APPENDIX © Theriva BIOLOGICS
Slide 33: Management team
Steven Shallcross Manel Cascalló PhD Vince Wacher PhD Chief Executive Officer, Chief General Director, EU Subsidiary Head Corporate Development Financial Officer Expertise in oncolytic adenovirus Nearly 30 years leading corporate Served as the Company’s CEO since clinical development, received strat
Slide 34: Oncolytic virus company comparison
THERIVA ONCOLYTICS COMPANY CG ONCOLOGY GENELUX REPLIMMUNE BIOLOGICS BIOTECH Ticker NYSE MKT: TOVX NASDAQ: CGON NASDAQ: GNLX NASDAQ:ONCY NASDAQ: REPL Market Cap¹ $3.7M $2.07B $102.3M $48.5M $753.9M Cretostimogene Product VCN-01 Olvi-Vec Pelareorep RP1, RP2 grenadenorepvec Virus Adenovirus 5 Adenoviru
Slide 35: VCN-01 in Pancreatic Cancer
VCN-01 IN PANCREATIC CANCER @ Theriva
Slide 36: Pancreatic cancer staging and epidemiology
PDAC >90% pancreatic cancer¹; median age 67-68 yr; 51% male² Male (per 100,000)³ N. America 9.3; W. Europe 9.9; E. Asia 7.0 Pancreatic Cancer 1-year (5-year) overall survival 24% (9%)³; median 4-6 months² Female (per 100,000)³ N. America 6.9; W. Europe 7.4; E. Asia 4.8 Borderline Locally Advanced Me
Slide 37: First-line treatments for pancreatic cancer
Radiotherapy if increases resection margins? First-Line ¥. Treatments (m)FOLFIRINOX, NALIRIFOX (ECOG 0-1) Neoadjuvant? Gemcitabine + nab-Paclitaxel (ECOG 0-2) Single agent gemcitabine, capecitabine, 5-FU (ECOG 3-4) ‘Bengtsson (2020) Sci Rep 10:16425. *Used in <20% of PDAC cases. *Identical to first-
Slide 38: VIRAGE vs NAPOLI 3 comparison
Statistics VIRAGE NAPOLI 3¹ Treatment Arm VCN-01+Gem/Nab Gem/Nab NALIRIFOX Gem/Nab Age (years) n 48 48 383 387 Median (range) 66.0 (41-86) 68.5 (52-85) 64 (20-85) 65 (36-82) Sex Female n (%) 25 (52.1) 26 (54.2) 179 (46.7) 157 (40.6) Male n (%) 23 (47.9) 22 (45.8) 204 (53.3) 230 (59.4) ECOG 0 n (%) 1
Slide 39: VCN-01 in Head & Neck Cancer
@ Theriva VCN-01 IN HEAD & NECK CANCER
Slide 40: Head and neck trial design
✓ ✓ ✓ VCN-01 3.3x10¹² vp (6) ARM I Durvalumab¹ CONCOMITANT Durvalumab 28-day HNSCC (6) BIOPSY SCR cycles starting Day 29 BIOPSY D8 BIOPSY D28 ARM II VCN-01 3.3x10¹² vp (6), 1x10¹³ vp (8) SEQUENTIAL Durvalumab 28-day HNSCC (14) Durvalumab¹ cycles starting Day 44 BIOPSY SCR BIOPSY D8 BIOPSY D28 | | |
Slide 41: Overall survival vs CPS in biopsies at Day 8
• Overall Survival vs CPS in Biopsies at Day 8 Spearman r = 0.7676 P (2-tailed) = 0.0050 •
Slide 42: VCN-01 may sensitize patients to subsequent therapy
VCN-01 MAY SENSITIZE PATIENTS TO SUBSEQUENT THERAPY Patients responded to subsequent chemotherapy after progressing with VCN-01 + durvalumab ICI Treatment 1st Line after 2nd Line after Progression (Pre-trial) Current Trial Current Trial Current Trial Median OS post-1st ICI Median PFS Median OS ORR O
Slide 43: Adverse reactions by CTCAE grade
Arm I - Concomitant Arm II - Sequential Arm II - Sequential Adverse Reactions (Dose 3,3E12 , n=6)² (Dose 3,3E12 , n=6)³ (Dose 1E13 , n=8)³ CTCAE Grade Grade 1-2 Grade ≥3 Grade 1-2 Grade ≥3 Grade 1-2 Grade ≥3 Pyrexia 2 (33,0%) - 5 (62,5%) - 3 (50%) - Influenza like illness 3 (50,0%) - 3 (37,5%) 2(25%
Slide 44: Gene set enrichment analysis of biopsies
Principal Component Analysis1 Most significant Reactome and KEGG pathways in GSEA (Gene Set Enrichment Analysis) 1 including all the Pre- and Post-treatment samples analysis D8 vs Pre-treat. analysis D28 vs Pre-treat. Pre-treatment Post-D8 Post-D28 Jové M et al. (2022) Poster 1231P: European Society
Slide 45: VCN-01 findings in R/M HNSCC
VCN-01 FINDINGS in R/M HNSCC Data support VCN-01 MOA and immune enhancing effects VCN-01 has an acceptable adverse event profile when administered prior to durvalumab (Imfinzi®) VCN-01 reaches tumors, has sustained replication and PH20 expression VCN-01 treatment led to downregulation of tumor matri
Slide 46: VCN-01 in Retinoblastoma
@ Theriva VCN-01 IN RETINOBLASTOMA
Slide 47: Retinoblastoma, a rare pediatric malignancy
RETINOBLASTOMA, A RARE PEDIATRIC MALIGNANCY * Retinoblastoma (Rb) is an orphan indication that accounts for ~2-3% of all childhood cancers! * 200-300 cases each year in the USA, EU2* ° VCN-01 selectivity enables development as an intravitreal treatment for Rb patients * VCN-01 could be used in combi
Slide 48: VCN-01 in retinoblastoma
VCN-01 IN RETINOBLASTOMA * Single center, open-label, dose escalation study of intravitreal (IVit) VCN-01"3 Promising Results in Patients Treated ° Children aged 1-12 years (n=9) with High Dose VCN-01 * Retinoblastoma that is recurrent or refractory to chemotherapy Reduced number and size of tumor v
Slide 49: Conserved retina and necrotic tumor images
⁹ Conserved retina • Necrotic tumor • • • ⁹
Slide 50: VCN-01 development in retinoblastoma
VCN-01 DEVELOPMENT IN RETINOBLASTOMA * Phase 1 ISS Completed H1 2024 ° Initial data demonstrate acceptable adverse event profile and one durable complete response * Developing a clinical protocol for an open-label, multinational study ° Retinoblastoma patients with vitreous seeds ° IVit VCN-01 in co
Slide 51: Bibliography
BIBLIOGRAPHY
Slide 52: Theriva oncolytic viruses key publications
THERIVA ONCOLYTIC VIRUSES KEY PUBLICATIONS Bayo-Puxan N et al. (2006) Role of the putative heparan sulfate glycosaminoglycar-binding site of the adenovirus type 5 fiber shaft on liver detargeting and knob- mediated retargeting. J Gen Virol 87:2487-2495, Bazan-Peregrino M et al. (2021) VCN-01 disrupt
Slide 53: Pancreatic cancer references
PANCREATIC CANCER REFERENCES DESCRIPTION, CLASSIFICATION, STAGING, STROMA Balachandran VP et al. (2019) Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities. Gastroenterology 156:2056-72 Christenson ES et al. (2020) Current and emerging therapies for patients wit
Slide 54: Retinoblastoma references
RETINOBLASTOMA (Rb) REFERENCES DESCRIPTION, CLASSIFICATION, STAGING American Academy of Ophthalmology. EyeWiki®. Retinoblastoma. https://eyewiki.org/Retinoblastoma American Cancer Society. Key statistics for retinoblastoma. https://www.cancer.org/cancer/retinoblastoma/about/key-statistics.html Cantu
Slide 55: OV company references
OV COMPANY REFERENCES CG Oncology CG0070 (cretostimogene grenadenorepvec) https://cgoncology.com Ramesh N et al. (2006) CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor-armed oncolytic adenovirus for the treatment of bladder cancer. Clin Cancer Res 12:305 Svatek R
Slide 56: OV company references
OV COMPANY REFERENCES Oncolytics Biotech: Pelareorep (formerly Reolysin®) https://oncolyticsbiotech.com Arnold D et al. Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients — Results from the GOBLET study